Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence (h-APC_EMR)
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
A NA clinical study on Colorectal Cancer and Polyp of Colon, this trial is completed. The trial is conducted by Centre hospitalier de l'Université de Montréal (CHUM) and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Apr 2025 — Sep 2025 [monthly]
Completed NA
Status: Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jan 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Dec 2022 — Jan 2024 [monthly]
Recruiting NA
Status: Completed → Recruiting
-
Apr 2021 — Dec 2022 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
-
Aug 2020 — Oct 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2019 — Aug 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre hospitalier de l'Université de Montréal (CHUM)
- Erbe Elektromedizin GmbH
- Penn State University
- Unity Health Toronto
- University of British Columbia
- University of Milan
For direct contact, visit the study record on ClinicalTrials.gov .